Work

Safety and efficacy of naxitamab plus modified dosing of GM-CSF for patients with high-risk neuroblastoma (HR-NB) in first complete remission (CR) or with primary refractory disease.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.e22012

Authors: Brian H. Kushner, Shakeel Modak, Ellen M. Basu, Fiorella Iglesias Cardenas, Kim Kramer, Stephen S. Roberts, Nai-Kong V. Cheung

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: Neuroblastoma Research and Treatments

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4379280638

Cites:

Cited by:

Related to: 10